Cancer Antibody Drug Conjugates Global Market Report 2025

The cancer antibody drug conjugates market size has grown rapidly in recent years. It will grow from $8.19 billion in 2024 to $9.17 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to rising incidence of cancer worldwide, increasing healthcare spending in developed nations, growing demand for targeted treatment options, surge in clinical use of precision therapies, expansion of oncology insurance coverage, and rising awareness of early cancer detection.

The cancer antibody drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $14.17 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to rising preference for personalized cancer therapies, increasing investment in oncology research programs by governments, growing focus on reducing chemotherapy side effects, surge in pharmaceutical collaborations for next generation cancer therapeutics, expansion of cancer screening initiatives in emerging economies, and rising penetration of specialty oncology clinics. Major trends in the forecast period include technological advancements in tumor specific antibody targeting, innovations in linker stability and payload delivery, advancements in companion diagnostic integration, developments in bispecific antibody engineering, research and development in immune stimulating conjugates, and technological progress in payload diversification.

The rising prevalence of cancer is expected to propel the growth of the cancer antibody drug conjugates market going forward. Prevalence of cancer refers to the total number of people, both newly diagnosed and previously diagnosed, who are alive with a history of cancer at a specific point in time. The prevalence of cancer is increasing due to lifestyle related risks such as poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, elevating the risk of developing various cancers. Cancer antibody drug conjugates aid in cancer treatment by delivering potent chemotherapy drugs directly to cancer cells, minimizing harm to healthy tissues. They enhance treatment precision by targeting specific tumor antigens, improving therapeutic effectiveness and reducing side effects for patients. For instance, in February 2025, according to Cancer Australia, an Australia based government agency, there were 4641 new pancreatic cancer cases in 2024, with 2414 in males and 2227 in females. Therefore, the rising prevalence of cancer is driving the growth of the cancer antibody drug conjugates market.

Major companies operating in the cancer antibody drug conjugates market are focusing on developing technologically advanced solutions such as cleavable tumor activated linker technology to enhance targeted delivery, treatment precision, and safety. Cleavable tumor activated linker technology refers to a specialized chemical system used in antibody drug conjugates that connects the cytotoxic drug to the antibody and releases it only when the antibody drug conjugate reaches the tumor microenvironment. For instance, in June 2025, Daiichi Sankyo Co. Ltd., a Japan based biopharmaceutical company, received United States Food and Drug Administration approval for Datroway datopotamab deruxtecan dlnk, a trophoblast cell surface antigen 2 TROP 2 directed antibody drug conjugate using a cleavable linker designed to treat adult patients with locally advanced or metastatic EGFR mutated non small cell lung cancer NSCLC who have received prior EGFR directed therapy and platinum based chemotherapy. The product features targeted payload release, improved tumour cell killing including bystander activity, and enhanced treatment tolerability. It improves precision in drug delivery and expands therapeutic options for difficult to treat solid tumours.

In December 2023, Pfizer Inc., a US based biopharmaceutical company, acquired Seagen Inc. for approximately forty three billion dollars. With this acquisition, Pfizer gains access to Seagen’s antibody drug conjugate technology and its portfolio of approved antibody drug conjugate based cancer therapies, thereby expanding its oncology capabilities while improving therapeutic reach and pipeline strength in the cancer antibody drug conjugates industry. Seagen Inc. is a US based biotechnology company specializing in the development and commercialization of cancer antibody drug conjugates.

Major companies operating in the cancer antibody drug conjugates market are Johnson & Johnson, Roche Holding AG, Merck and Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Byondis BV, Adienne Pharma and Biotech SA, Helix BioPharma Corp., Adcytherix SAS

North America was the largest region in the cancer antibody drug conjugates market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer antibody drug conjugates report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cancer antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The cancer antibody drug conjugates market research report is one of a series of new reports that provides cancer antibody drug conjugates market statistics, including the cancer antibody drug conjugates industry global market size, regional shares, competitors with the cancer antibody drug conjugates market share, detailed cancer antibody drug conjugates market segments, market trends, and opportunities, and any further data you may need to thrive in the cancer antibody drug conjugates industry. This cancer antibody drug conjugates market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Cancer antibody drug conjugates are targeted biopharmaceuticals made of monoclonal antibodies connected to powerful cytotoxic drugs. These antibodies selectively attach to cancer cell antigens, delivering the drug directly to malignant cells while limiting damage to healthy tissues. This targeted method improves treatment effectiveness, reduces side effects, and offers new therapeutic options for patients with cancers that do not respond to standard therapies.

The main types of antibodies used in cancer drug conjugates include monoclonal antibodies, bispecific antibodies, low molecular weight antibodies, and polyclonal antibodies. Monoclonal antibodies are laboratory produced molecules designed to accurately identify and bind to specific antigens on target cells, allowing targeted therapeutic action. The different mechanisms of action involved are cell death signal inducers, microtubule disruptors, deoxyribonucleic acid damage inducers, and immune checkpoint inhibitors, and they use technologies such as cleavable linkers and non cleavable linkers. These drug conjugates are indicated for breast cancer, blood cancer, lung cancer, gastrointestinal cancer, and prostate cancer, and they serve several end users, including hospitals, specialty clinics, and research institutes.

The cancer antibody drug conjugates market consists of sales of cytotoxic payloads, conjugation kits, targeted delivery agents, antibody-drug conjugates, tumor-targeting biomarkers, and companion diagnostic test kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.